We hypothesized that a low dose BNZ treatment in combination with a therapeutic vaccine (TSA-1-C4 and Tc24-C4 recombinant antigens in a formulation with a synthetic TLR-4 agonist-adjuvant, E6020-SE) given during early chronic infection could prevent cardiac disease progression and provide antigen-specific T cell immunity. The gene discussed is TLR4; the disease is heart disorder.